Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Prologis Inc (PLD) Price & Performance

Medpace Holdings IncTrade
Prologis IncTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Prologis Inc — how do they compare? Medpace Holdings Inc trades at $601.74 (market cap $16.90B), while Prologis Inc trades at $139.27 (market cap $132.57B). The key difference: Prologis Inc is far larger — about 7.8× Medpace Holdings Inc's market cap, and Prologis Inc pays a 3.07% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

MEDPPLD
Market Cap
$16.90B$132.57B
Sector
TechnologyReal Estate
52-Week High
$620.59$149.96
52-Week Low
$393.42$104.81
Enterprise Value
$16.52B$167.31B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.

Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.

Prologis Inc

Prologis (PLD) trades at $138.73, down 1.02% today, with a bearish technical signal from moving averages but strong fundamentals including a 45.79% net income margin and consistent earnings beats. Recent news highlights a major acquisition of SEGRO for $18.8 billion, expanding its European footprint, alongside a common stock offering to fund growth. Cash flow trends show volatility, with 2025 net cash flow negative at -$172.94 million but projected to rebound in 2026.

The outlook is positive due to robust earnings growth and strategic expansion, but risks include rising debt levels and integration challenges from the SEGRO deal. Analysts are bullish with a $159.22 consensus target, suggesting 15% upside, supported by institutional holdings and dividend payouts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Prologis Inc

Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.

Read more on PLD